NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

How many people have received a coronavirus vaccine?

Tracking COVID-19 vaccination rates is crucial to understand the scale of protection against the virus, and how this is distributed across the global population.

A global, aggregated database on COVID-19 vaccination rates is essential to monitor progress, but it is unfortunately not yet available. This dataset provides the last weekly update of vaccination rates.

Last update

June 2021

Content

Colums description: 1. iso_code: ISO 3166-1 alpha-3 – three-letter country codes 2. continent: Continent of the geographical location 3. location: Geographical location 4. date: Date of observation 5. total_cases: Total confirmed cases of COVID-19 6. new_cases: New confirmed cases of COVID-19 7. new_cases_smoothed: New confirmed cases of COVID-19 (7-day smoothed) 8. total_deaths: Total deaths attributed to COVID-19 9. new_deaths: New deaths attributed to COVID-19 10. new_deaths_smoothed: New deaths attributed to COVID-19 (7-day smoothed) 11. total_cases_per_million: Total confirmed cases of COVID-19 per 1,000,000 people 12. new_cases_per_million: New confirmed cases of COVID-19 per 1,000,000 people 13. new_cases_smoothed_per_million: New confirmed cases of COVID-19 (7-day smoothed) per 1,000,000 people 14. total_deaths_per_million: Total deaths attributed to COVID-19 per 1,000,000 people 15. new_deaths_per_million: New deaths attributed to COVID-19 per 1,000,000 people 16. new_deaths_smoothed_per_million: New deaths attributed to COVID-19 (7-day smoothed) per 1,000,000 people 17. reproduction_rate: Real-time estimate of the effective reproduction rate (R) of COVID-19. See http://trackingr-env.eba-9muars8y.us-east-2.elasticbeanstalk.com/FAQ 18. icu_patients: Number of COVID-19 patients in intensive care units (ICUs) on a given day 19. icu_patients_per_million: Number of COVID-19 patients in intensive care units (ICUs) on a given day per 1,000,000 people 20. hosp_patients: Number of COVID-19 patients in hospital on a given day 21. hosp_patients_per_million: Number of COVID-19 patients in hospital on a given day per 1,000,000 people 22. weekly_icu_admissions: Number of COVID-19 patients newly admitted to intensive care units (ICUs) in a given week 23. weekly_icu_admissions_per_million: Number of COVID-19 patients newly admitted to intensive care units (ICUs) in a given week per 1,000,000 people 24. weekly_hosp_admissions: Number of COVID-19 patients newly admitted to hospitals in a given week 25. weekly_hosp_admissions_per_million: Number of COVID-19 patients newly admitted to hospitals in a given week per 1,000,000 people 26. total_tests: Total tests for COVID-19 27. new_tests: New tests for COVID-19 28. new_tests_smoothed: New tests for COVID-19 (7-day smoothed). For countries that don't report testing data on a daily basis, we assume that testing changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window 29. total_tests_per_thousand: Total tests for COVID-19 per 1,000 people 30. new_tests_per_thousand: New tests for COVID-19 per 1,000 people 31. new_tests_smoothed_per_thousand: New tests for COVID-19 (7-day smoothed) per 1,000 people 32. tests_per_case: Tests conducted per new confirmed case of COVID-19, given as a rolling 7-day average (this is the inverse of positive_rate) 33. positive_rate: The share of COVID-19 tests that are positive, given as a rolling 7-day average (this is the inverse of tests_per_case) 34. tests_units: Units used by the location to report its testing data 35. total_vaccinations: Number of COVID-19 vaccination doses administered 36. total_vaccinations_per_hundred: Number of COVID-19 vaccination doses administered per 100 people 37. stringency_index: Government Response Stringency Index: composite measure based on 9 response indicators including school closures, workplace closures, and travel bans, rescaled to a value from 0 to 100 (100 = strictest response) 38. population: Population in 2020 39. population_density: Number of people divided by land area, measured in square kilometers, most recent year available 40. median_age: Median age of the population, UN projection for 2020 41. aged_65_older: Share of the population that is 65 years and older, most recent year available 42. aged_70_older: Share of the population that is 70 years and older in 2015 43. gdp_per_capita: Gross domestic product at purchasing power parity (constant 2011 international dollars), most recent year available 44. extreme_poverty: Share of the population living in extreme poverty, most recent year available since 2010 45. cardiovasc_death_rate: Death rate from cardiovascular disease in 2017 (annual number of deaths per 100,000 people) 46. diabetes_prevalence: Diabetes prevalence (% of population aged 20 to 79) in 2017 47. female...

NOTE: This dataset replaces a previous one. Please see below. Chicago residents who are up to date with COVID-19 vaccines by ZIP Code, based on the reported home address and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). “Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria: People ages 5 years and older: · Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season. Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine. This dataset takes the place of a previous dataset, which covers doses administered from December 15, 2020 through September 13, 2023 and is marked as historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-ZIP-Code/553k-3xzc. Data Notes: Weekly cumulative totals of people up to date are shown for each combination ZIP Code and age group. Note there are rows where age group is "All ages" so care should be taken when summing rows. Coverage percentages are calculated based on the cumulative number of people in each ZIP Code and age group who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. For ZIP Codes mostly outside Chicago, coverage percentages are not calculated reliable Chicago-only population counts are not available. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller ZIP Codes with smaller populations. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage by geography. All coverage percentages are capped at 99%. Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Individuals may receive vaccinations that are not recorded in the Illinois immunization registry, I-CARE, such as those administered in another state, causing underestimation of the number individuals who are up to date. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate records for a person and underestimate the number of people who are up to date. For all datasets related to COVID-19, please

CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

NOTE: As of 2/16/2023 this table is no longer being updated. For information on COVID-19 Updated (Bivalent) Booster Coverage, go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Race/8267-bg4w.

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by age at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This table shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 by race / ethnicity and age group.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple races.

A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities suggest that in at least some cases NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the classification of records as NH Unknown Race or NH Other Race.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: This dataset takes the place of the original "COVID-19 Vaccinations by Race/Ethnicity" dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/xkga-ifz3 ), which will not be updated after 5/20/2021 and “COVID-19 Vaccinations by Race / Ethnicity” dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/ybkg-w5x2), which will not be updated after 10/20/2021.

This site provides historical data beginning June 14, 2023, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States” site titled “Percent of Total Population Who Are Up to Date with COVID-19 Vaccines” Definition for Up to Date: For surveillance purposes people are ‘Upto Date’ with COVID-19 vaccines based on the following criteria: People ages 6 years and older: Are up to date if they received 1 updated Pfizer-BioNTech or Moderna COVID-19 vaccine. Children ages 6 months to 5 years who received the Pfizer-BioNTech COVID-19 vaccine: Are up to date if: At ages 6 months to 4 years, they received 3 COVID-19 vaccine doses, including at least 1 updated COVID-19 dose; at age 5 years, they received at least 1 updated COVID-19 vaccine dose. Children ages 6 months to 5 years who received the Moderna COVID-19 vaccine: Are up to date if they received 2 Moderna COVID-19 vaccine doses, including at least 1 updated COVID-19 vaccine dose. People who are unable or choose not to get a recommended mRNA vaccine: Are up to date if they receive the Novavax COVID-19 vaccine doses approved for their age group. CDC uses US Census estimates for the total populations within each specified demographic group regardless of prior vaccination status as denominators. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

NOTE: As of 2/16/2023, this page is no longer being updated. This table shows the number and percent of people that have initiated COVID-19 vaccination and are fully vaccinated by race / ethnicity and town. It includes people of all ages. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple race. A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities suggest that NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the exclusion of records classified as NH Unknown Race or NH Other Race. Town of residence is verified by geocoding the reported address and then mapping it a town using municipal boundaries. If an address cannot be geocoded, the reported town is used. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census) or potential data reporting errors. The population denominators for these town- and age-specific coverage estimates are based on 2014 census estimates. This is the most recent year for which reliable town- and age-specific estimates are available. (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Town-Population-with-Demographics). Changes in the size and composition of the population between 2014 and 2021 may results in inaccuracy in vaccine coverage estimates. For example, the size of the Hispanic population may be underestimated in a town given the reported increase in the size of the Hispanic population between the 2010 and 2020 censuses resulting in inflated vaccine coverage estimates. The 2014 census data are grouped in 5-year age bands. For vaccine coverage age groupings not consistent with a standard 5-year age band, each age was assumed to be 20% of the total within a 5-year age band. However, given the large deviation from this assumption for Mansfield because of the presence of the University of Connecticut, the age distribution observed in the 2010 census for the age bands 15 to 19 and 20 to 24 was used to estimate the population denominators. This table does not included doses administered to CT residents by out-of-state providers or by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) because they are not yet reported to CT WiZ (the CT immunization Information System). It is expected that these data will be added in the future. Caution should be used when interpreting coverage estimates for towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while study

NOTE: This dataset replaces a previous one. Please see below.

Chicago residents who are up to date with COVID-19 vaccines by Healthy Chicago Equity Zone (HCEZ), based on the reported address, race-ethnicity, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE).

Healthy Chicago Equity Zones is an initiative of the Chicago Department of Public Health to organize and support hyperlocal, community-led efforts that promote health and racial equity. Chicago is divided into six HCEZs. Combinations of Chicago’s 77 community areas make up each HCEZ, based on geography. For more information about HCEZs including which community areas are in each zone see: https://data.cityofchicago.org/Health-Human-Services/Healthy-Chicago-Equity-Zones/nk2j-663f

“Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria:

People ages 5 years and older:
·Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season.

Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine.

This dataset takes the place of a previous dataset, which cover doses administered from December 15, 2020 through September 13, 2023 and is marked as historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-Region-Age-and-Race-Ethni/n7f2-e2kq.

Data notes:

Weekly cumulative totals of people up to date are shown for each combination of race-ethnicity and age group within an HCEZ. Note that each HCEZ has a row where HCEZ is “Citywide” and each HCEZ has a row where age is "All" and race-ethnicity is “All Race/Ethnicity Groups” so care should be taken when summing rows.

Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity within an HCEZ) who are up to date, divided by the estimated number of people in that subgroup. Population counts are from the 2020 U.S. Decennial Census. Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group within an HCEZ. All coverage percentages are capped at 99%. Summing all race/ethnicity group populations to obtain citywide populations may provide a population count that differs slightly from the citywide population count listed in the dataset. Differences in these estimates are due to how community area populations are calculated.

Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Individuals may receive vaccinations that are not recorded in the Illinois immunization registry, I-CARE, such as those administered in another state, causing underestimation of the number individuals who are up to date. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate records for a person and underestimate the number of people who are up to date.

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19.

Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau 2020 Decennial Census

A phase 1/2, open-label clinical trial in individuals, 18 years of age and older, who are in good health, have no known history of Coronavirus Disease 2019 (COVID-19) or Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and meet all other eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of a delayed (>/=12 weeks) vaccine boost on a range of Emergency Use Authorization (EUA)-dosed COVID-19 vaccines (mRNA-1273, and mRNA-1273.211 manufactured by ModernaTX, Inc.; BNT162b2 manufactured by Pfizer/BioNTech; or Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson & Johnson). This is an adaptive design and may add arms (and increase sample size) as vaccines are awarded EUA and/or variant lineage spike vaccines are manufactured or become available. Enrollment will occur at up to twelve domestic clinical research sites.

This study includes two cohorts. Cohort 1 will include approximately 880 individuals (50 subjects/group; Groups 1E-11E) greater than 18 years of age and older, stratified into two age strata (18-55 years and >/=56 years) who previously received COVID-19 vaccine at Emergency Use Authorization dosing (EUA) (two vaccinations of mRNA-1273 at the 100 mcg dose, two vaccinations of BNT162b2 at the 30 mcg dose, or one vaccination of Ad26.COV2.S at the 5x10^10 vp dose). Groups 15E-17E will enroll 60 subjects, split (approximately evenly) between age strata as able. Those subjects will be offered enrollment into this study >/=12 weeks after they received the last dose of their EUA vaccine. Subjects will receive a single open-label intramuscular (IM) injection of the designated delayed booster vaccine and will be followed through 12 months after vaccination: 1) Group 1E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp followed by a 100-mcg dose of mRNA-1273, Group 4E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 7E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S 5x10^10 vp followed by a 30-mcg dose of BNT162b2, Group 10E - previously EUA-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp followed by a 100-mcg dose of mRNA-1273.211; Group 12E - previously EUA-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp followed by a 50-mcg dose of mRNA-1273; Group 15E - previously EUA-dosed vaccination with Janssen (two doses for Group 15E) - Ad26.COV2.S at 5x1010 vp followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV-2 rS vaccine with 50 mcg Matrix-M); 2) Group 2E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 100-mcg dose of mRNA-1273, Group 5E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 8E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 30-mcg dose of BNT162b2, Group 13E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 50-mcg dose of mRNA-1273; Group 16E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV2 rS vaccine with 50 mcg Matrix-M); 3) Group 3E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 100-mcg dose of mRNA-1273. Group 6E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 9E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 30-mcg dose of BNT162b2, Group 11E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 100-mcg dose of mRNA-1273.211. Group 14E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 50-mcg dose of mRNA-1273, Group 17E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV2 rS vaccine with 50 mcg Matrix-M).

A telephone visit will occur one week after each primary EUA vaccination and one week after the booster dose. In person follow-up visits will occur on 14 days following completion of EUA vaccinations and on days 14, and 28 days after the booster dose, as well as 3, 6, and 12 months post the booster vaccination. Additional pools of subjects can be included if needed as additional COVID-19 vaccines are awarded EUA.

The primary objectives of this study are 1) to evaluate the safety and reactogenicity of delayed heterologous or homologous vaccine doses after EUA dosed vaccines, and 2) to evaluate the breadth of the humoral immune responses of heterologous and homologous delayed boost regimens following EUA dosing.

NOTE: After 5/20/2021, this dataset will no longer be updated and will be replaced by the new dataset: "COVID-19 Vaccinations by Race/Ethnicity" (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/4z97-pa4q).

Cumulative number and percent of people who initiated COVID-19 vaccination and who are fully vaccinated by race/ethnicity for select age groups (ages 16+, ages 65-74, and ages 75+) as reported by providers.

Population estimates are based on 2019 CT population estimates. The 2019 CT population data which is the most recent year available. The tables that show the percent vaccinated by town and age group are an exception. These tables use 2014 CT population estimates. This the most recent year for which reliable estimates by town and age are available.

A person who has received one dose of any vaccine is considered to have received at least one dose. A person is considered fully vaccinated if they have received 2 doses of the Pfizer or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. The number with At Least One Dose and the number Fully Vaccinated add up to more than the total number of doses because people who received the Johnson & Johnson vaccine fit into both categories.

In this data, a person with reported Hispanic or Latino ethnicity is considered Hispanic regardless of reported race. The category Unknown includes unknown race and/or ethnicity.

The percent of people classified as Other race (not specified) and Multiple race in CT WiZ (for COVID-19 vaccine records and all other vaccine records) are higher than would be expected based on census data. Other race, Multiple race and Unknown include people who should be classified as Asian, Black, Hispanic and White. Therefore, the coverage of these groups may be underestimated and should be interpreted with caution.

The estimates for the category Multiple Races are considered unreliable

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

Note: As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

NOTE: As of 2/16/2023, this page is no longer being updated.

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by gender at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated grouped by gender and have additional dose 1 grouped by gender.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. Population estimates are based on 2019 CT population estimates. Bivalent booster administrations are not included in the additional dose 1 calculations.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional bivalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed.

The percent with at least one dose may be over-estimated and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: As part of continuous data quality improvement efforts, duplicate records

NOTE: As of 2/16/2023, this table is not being updated. For data on COVID-19 updated (bivalent) booster coverage by town please to go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Town/bqd5-4jgh.

This table shows the number and percent of residents of each CT town that have initiated COVID-19 vaccination, are fully vaccinated and who have received additional dose 1.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Percentages are calculated using 2019 census data (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Annual-Town-and-County-Population-for-Connecticut).

Town of residence is verified by geocoding the reported address and then mapping it to a town using municipal boundaries. If an address cannot be geocoded, the reported town is used, if available. People for whom an address is not currently available are shown in this table as “Address pending validation”. Out-of-state residents vaccinated by CT providers are excluded from the table.

Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated when records for an individual cannot be linked because of differences in how names or date of birth are reported.

Caution should be used when interpreting coverage estimates for towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while studying remotely in his/her hometown, the student may be counted as a vaccine recipient in that town.

SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. Towns with a "yes" in the "Has SVI tract >0.75" field are those that have at least one census tract that is in the top quartile of vulnerability (e.g., a high-need area). 34 towns in Connecticut have at least one census tract in the top quartile for vulnerability.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ.  Data reported here reflect the vaccination records currently reported to CT WiZ.

Note: This dataset takes the place of the original "COVID-19 Vaccinations by Town" dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town/pdqi-ds7f) , which will not be updated after 4/15/2021. A breakdown of vaccinations by town and by age group is also available here: https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town-and-Age-Group/gngw-ukpw .

As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

NOTE: As of 4/15/2021, this dataset will no longer be updated and will be replaced by two new datasets: 1) "COVID-19 Vaccinations by Town" (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town/x7by-h8k4) and "COVID-19 Vaccinations by Town and Age Group" (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town-and-Age-Group/gngw-ukpw).

A summary of COVID-19 vaccination coverage in Connecticut by town. Records without an address could not be included in town vaccine coverage estimates. Total population estimates are based on 2019 data.

A person who has received one dose of any vaccine is considered to have received at least one dose. A person is considered fully vaccinated if they have received 2 doses of the Pfizer or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. The number with At Least One Dose and the number Fully Vaccinated add up to more than the total number of doses because people who received the Johnson & Johnson vaccine fit into both categories.

SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. Towns with a "yes" in the "Has SVI tract >0.75" field are those that have at least one census tract that is in the top quartile of vulnerability (e.g., a high-need area). 34 towns in Connecticut have at least one census tract in the top quartile for vulnerability.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

This open dataset shows data on Cambridge residents who have received a COVID-19 vaccine at any location (e.g., mass vaccination site, pharmacy, doctor's office). These data come from the Massachusetts Department of Public Health's weekly report on vaccine doses administered by municipality. The report is released on Thursdays. This open dataset includes data going back several weeks and complements another open dataset called "Cambridge Vaccine Demographics," which shows data for the latest week (https://data.cambridgema.gov/Public-Health/Cambridge-Vaccination-Demographics/66td-u88k)

The Moderna and Pfizer vaccines require two doses administered at least 28 days apart in order to be fully vaccinated. The J&J (Janssen) vaccine requires a single dose in order to be fully vaccinated.

The category "Residents Who Received at Least One Dose" reflects the total number of individuals in the fully and partially vaccinated categories. That is, this category comprises individuals who have received one or both doses of the Moderna/Pfizer vaccine or have received the single dose J&J (Janssen) vaccine.

The category "Fully Vaccinated Residents" comprises individuals who have received both doses of the Moderna/ Pfizer vaccine or the single-dose J&J vaccine.

The category "Partially Vaccinated Residents" comprises individuals who have received only the first dose of the Moderna/Pfizer vaccine.

Source: Weekly COVID-19 Municipality Vaccination Report. Massachusetts releases updated data each Thursday at 5 p.m.

NOTE: As of 2/16/2023, this page is not being updated. For data on updated (bivalent) COVID-19 booster vaccination click here: https://app.powerbigov.us/view?r=eyJrIjoiODNhYzVkNGYtMzZkMy00YzA3LWJhYzUtYTVkOWFlZjllYTVjIiwidCI6IjExOGI3Y2ZhLWEzZGQtNDhiOS1iMDI2LTMxZmY2OWJiNzM4YiJ9 This table shows the number and percent of people that have initiated COVID-19 vaccination and are fully vaccinated by CT census tract (including residents of all ages). It also shows the number of people who have not received vaccine and who are not yet fully vaccinated. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. The percent with at least one dose many be over-estimated and the percent fully vaccinated may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Population data obtained from the 2019 Census ACS (www.census.gov) Geocoding is used to determine the census tract in which a person lives. People for who a census tract cannot be determined based on available address data are not included in this table. DPH recommends that these data are primarily used to identify areas that require additional attention rather than to establish and track the exact level of vaccine coverage. Census tract coverage estimates can play an important role in planning and evaluating vaccination strategies. However, inaccuracies in the data that are inherent to population surveillance may be magnified when analyses are performed down to the census tract level. We make every effort to provide accurate data, but inaccuracies may result from things like incomplete or inaccurate addresses, duplicate records, and sampling error in the American Community Survey that is used to estimate census tract population size and composition. These things may result in overestimates or underestimates of vaccine coverage. Some census tracts are suppressed. This is done if the number of people vaccinated is less than 5 or if the census population estimate is considered unreliable (coefficient of variance > 30%). Coverage estimates over 100% are shown as 100%. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records currently reported to CT WiZ. Caution should be used when interpreting coverage estimates in towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while studying remotely in his/her hometown, the student may be counted as a vaccine recipient in that town. As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021. As of 1/13/2021, census tract level data are provider by town for all ages. Data by age group is no longer available.

NOTE: As of 2/16/2023, this page is not being updated. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 grouped by whether they live in an SVI Priority Zip Code. People with an out-of-state zip code are excluded from this analysis. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary vaccine series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional dose of COVID-19 vaccine is considered to have had additional dose 1. The additional monovalent dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. SVI scores were calculated for each zip code in CT. The zip codes in the top 20% were designated as SVI Priority Zip Codes. Percentages are based on 2018 zip code population data supplied by ESRI corporation. The percent with at least one dose many be over-estimated and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ.  Data reported here reflect the vaccination records currently reported to CT WiZ. Note: As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

As of 10/27/2022, this dataset will no longer update. To continue to access updated vaccination metrics given to SF residents, including newly added bivalent boosters, please navigate to the following page: COVID-19 Vaccinations Given to SF Residents Over Time.

A. SUMMARY This dataset represents the COVID-19 vaccinations given to San Franciscans over time. All vaccines given to people who live in San Francisco are included, no matter where the vaccination took place (the vaccine may have been administered in San Francisco or outside of San Francisco).

B. HOW THE DATASET IS CREATED Information on doses administered to those who live in San Francisco is from the California Immunization Registry (CAIR), run by the California Department of Public Health (CDPH).

C. UPDATE PROCESS Updated daily via automated process

D. HOW TO USE THIS DATASET Different vaccines have different dosage requirements. For example, the Moderna and the Pfizer vaccines require two doses in order for a resident to complete their primary vaccine series (as of December 21, 2021). Each dose is recorded separately in its respective dataset column. Other vaccines, such as Johnson & Johnson, would only require a single dose for a resident to complete their primary vaccine series (as of December 21, 2021). The Pfizer vaccine for children under 5 requires three separate doses. Single dose vaccines counts are recorded in a separate column.

Summing the NEW_1ST_DOSES, NEW_2ND_DOSES, NEW_SINGLE_DOSES columns would give you the total count of primary vaccine series doses administered on a given day. To count the number of individuals who have completed their primary vaccine series on a given day, use the NEW_SERIES_COMPLETED column. To count the number of individuals vaccinated (with any primary series dose) for the first time on a given day, use the NEW_RECIPIENTS column.

To count the number of individuals who got a vaccine booster on a given day, use the NEW_BOOSTER_RECIPIENTS column. To count the number of booster doses administered on a given day, use the NEW_BOOSTER_DOSES column. To count the total number of individuals who have received a booster over time, use the CUMULATIVE_BOOSTER_RECIPIENTS column. To count the total number of booster doses that have been administered over time, use the CUMULATIVE_BOOSTER_DOSES column.

In our public dashboards we combine this dataset with the US Census's 2019 five-year American Community Survey population estimates to estimate the percent of San Franciscans vaccinated.

Context

The research shows that the U.S. had secured 1.01 billion doses from six different companies up to November 20 which represents the highest quantity of any government apart from India which has made agreements for 1.6 billion. Pfizer/BioNTech and Moderna both account for 100 million U.S. doses each while the U.S. is also set for 500 million doses of the vaccine being developed by the University of Oxford and AstraZeneca.

https://www.statista.com/chart/23660/umber-of-doses-of-covid-19-vaccines-secured-by-the-us/

Content

This chart shows the number of doses of Covid-19 vaccines secured by the U.S. as of November 20, 2020.

Acknowledgements

Niall McCarthy, Data Journalist.

https://www.statista.com/chart/23660/umber-of-doses-of-covid-19-vaccines-secured-by-the-us/

Inspiration

Covid-19 Pandemic.

Context

Yesterday, hopes soared that an end to the pandemic may finally be in sight after an interim analysis showed Pfizer/BioNTech's vaccine candidate provided 90 percent protection in trials. It performed much better than experts had hoped for and manufacturing has already started with Pfizer stating it hopes to supply 50 million doses in 2020 and 1.3 billion doses in 2021. Pfizer chairman and chief executive Albert Bourla said that “Today is a great day for science and humanity. The first set of results from our phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” adding that “we are reaching this critical milestone in our vaccine development programme at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”

The rush to develop a Covid-19 vaccine has gained traction in recent months and a representative from the Russian health ministry also claimed the country's Sputnik V is up to 90 percent effective. Great hopes have also been pinned on a coronavirus vaccine candidate being developed by the University of Oxford that successfully triggered a strong immune response in trials involving 1,077 people. Scientific journal The Lancet had published hugely promising results of Phase I/II trials in July for the University of Oxford vaccine and it provoked a T cell response within 14 days of vaccination and an antibody response within 28 days.

https://www.statista.com/chart/22325/number-of-covid-19-vaccine-candidates/

Content

Vaccines generally take years to develop but candidates are now being developed at an unprecedented pace. Nearly 200 Covid-19 vaccine candidates are now listed by the World Health Organization, according to The Guardian and several are already in advanced testing. The data shows that the bulk of candidates are in the pre-clinical stage of testing where the vaccine is given to animals to see if it triggers an immune response. 39 are in phase I trials where it is administered to a small group of people to determine whether it is safe. 18 are in phase II where the candidate is given to hundreds of people to evaluate further safety issues as well as dosage. The last stage is Phase III, of which 11 candidates are currently in, and it involves thousands of people receiving the vaccine to eliminate any final safety fears, particularly considering side effects.

Acknowledgements

Niall McCarthy, Data Journalist. https://www.statista.com/chart/22325/number-of-covid-19-vaccine-candidates/

Inspiration

Covid-19